Site intended for UK audience

Our vision

GL Pharma was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and has a history of more than 75 years.

Welcome to GL Pharma – Shaping the Future of Healthcare Through Innovation and Excellence. Our visionary outlook drives us to redefine pharmaceutical solutions and make a lasting impact on global healthcare. With an unwavering commitment to pioneering research, advanced technology, and uncompromising quality, we aspire to enhance lives by developing cutting-edge medications and therapies. At GL Pharma, we envision a world where every individual has access to safe, effective, and affordable treatments. Join us in our journey as we strive to transform the landscape of healthcare, one breakthrough at a time.

Management team

Martin Bartenstein

CEO

 

Ilse Bartenstein

CEO

 

Our history

1947 - 1948​

Foundation of Lannacher Heilmittel in Lannach/Graz and Gerot Pharmazeutika in Vienna

1966​

Bartenstein family takes over Lannacher Heilmittel

1997​

Acquisition of Gerot Pharmazeutika by Lannacher Heilmittel

2003​

Start of operations ​at the state-of-the-art solid forms production site Lannach/Graz

2009​

Lannacher and Gerot merge under the brand Gerot Lannach

2012​

Strategic cooperation with Bausch Health in Russia and CIS markets

2020​

Doubling of production capacity as a result of Lannach/Graz production site expansion

2023​

Rebranding of GL Pharma

Company

Facts & Figures

Markets

Our products can be found in more than 50 markets worldwide. GL Pharma has 16 distribution structures in Europe and a subsidiary in Central America.

Headcount

~1.200 employees

Revenues

280 MEUR, 400 MEUR group revenue including Genericon Pharma

Production Volume

~ 5 bn single doses​ per year

Transparency

In healthcare, trust is fundamental.

As a responsible company, GL Pharma is committed to transparency. Within the framework of the EFPIA Transparency Code, we disclose financial contributions to medical professionals.